MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE: A POOLED SAFETY ANALYSIS OF 3 CLINICAL TRIALS

被引：0

作者：

Moreau, P. ^{[1
]}

Dimopoulos, M. A. ^{[2
]}

Richardson, P. G. ^{[3
]}

Siegel, D. ^{[4
]}

Palumbo, A. ^{[5
]}

Cavo, M. ^{[6
]}

Corradini, P. ^{[7
]}

Weisel, K. ^{[8
]}

Delforge, M. ^{[9
]}

O'Gorman, P. ^{[10
]}

Song, K. ^{[11
]}

Sternas, L. ^{[12
]}

Biyukov, T. ^{[13
]}

Hong, K. ^{[12
]}

Herring, J. ^{[12
]}

Yu, X. ^{[12
]}

Zaki, M. H. ^{[12
]}

San Miguel, J. ^{[14
]}

机构：

[1] Univ Hosp Hotel Dieu, Nantes, France

[2] Univ Athens, Athens, Greece

[3] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA

[4] John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Turin, Turin, Italy

[6] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[7] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] Univ Hosp Tubingen, Tubingen, Germany

[9] Univ Hosp Leuven, Leuven, Belgium

[10] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Dublin, Ireland

[11] Vancouver Gen Hosp, Vancouver, BC, Canada

[12] Celgene Corp, Summit, NJ USA

[13] Celgene Int Sarl, Boudry, Switzerland

[14] Univ Navarra Clin, CIMA, IDISNA, Pamplona, Spain

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

E1284

引用

页码：531 / 531

页数：1

共 50 条

[1] Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Moreau, Philippe
Dimopoulos, Meletios A.
Richardson, Paul G.
Siegel, David S.
Cavo, Michele
Corradini, Paolo
Weisel, Katja
Delforge, Michel
O'Gorman, Peter
Song, Kevin
Chen, Christine
Bahlis, Nizar
Oriol, Albert
Hansson, Markus
Kaiser, Martin
Anttila, Pekka
Raymakers, Reinier
Joao, Cristina
Cook, Gordon
Sternas, Lars
Biyukov, Tsvetan
Slaughter, Ana
Hong, Kevin
Herring, Jennifer
Yu, Xin
Zaki, Mohamed
San-Miguel, Jesus
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (03) : 199 - 206
[2] A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE
Palumbo, A.
Dimopoulos, M. A.
Richardson, P. G.
Siegel, D. S.
Cavo, M.
Corradini, P.
Weisel, K. C.
Delforge, M.
Chen, C.
Goldschmidt, H.
Jagannath, S.
Lockhorst, H. M.
Moreau, P.
Plesner, T.
Sternas, L.
Peluso, T.
Hong, K.
Herring, J.
Yu, X.
Zaki, M. H.
San Miguel, J.
HAEMATOLOGICA, 2016, 101 : 535 - 536
[3] Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
Siegel, David S.
Weisel, Katja C.
Dimopoulos, Meletios A.
Baz, Rachid
Richardson, Paul
Delforge, Michel
Song, Kevin W.
San Miguel, Jesus F.
Moreau, Philippe
Goldschmidt, Hartmut
Cavo, Michele
Jagannath, Sundar
Yu, Xin
Hong, Kevin
Sternas, Lars
Zaki, Mohamed
Palumbo, Antonio
LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2833 - 2838
[4] MANAGEMENT OF ADVERSE EVENTS IN THE STRATUS TRIAL, A PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Cavo, M.
Dimopoulos, M. A.
Moreau, P.
Palumbo, A.
Corradini, P.
Weisel, K.
Ocio, E.
Doyen, C.
Anttila, P.
Raymakers, R.
San Miguel, J.
Yu, X.
Milller, N.
Herring, J.
Slaughter, A.
Peluso, T.
Sternas, L.
Zaki, M.
Delforge, M.
HAEMATOLOGICA, 2015, 100 : 253 - 254
[5] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, Ashraf
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander
Dogan, Ahmet
Rapoport, Aaron P.
Kocoglu, Mehmet
Lederer, Emily
Philip, Sunita
Milliron, Todd
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
BLOOD, 2017, 130 (10) : 1189 - 1197
[6] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
De Miguel, D.
Gil, A.
Golbano, N.
Diaz, M.
Guillen, H.
Vazquez, A.
Pinedo, B.
HAEMATOLOGICA, 2017, 102 : 790 - 791
[7] Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.
Moreau, Philippe
Dimopoulos, Meletios A.
Richardson, Paul G.
Siegel, David Samuel DiCapua
Palumbo, Antonio
Cavo, Michele
Corradini, Paolo
Weisel, Katja
Delforge, Michel
O'Gorman, Peter
Song, Kevin W.
Sternas, Lars Axel
Peluso, Teresa
Hong, Kevin
Herring, Jennifer
Yu, Xin
Zaki, Mohamed H.
Miguel, Jesus San
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
Matous, J.
Siegel, D.
Lonial, S.
Harvey, R. D.
Kasserra, C.
Li, Y.
Chen, M.
Doerr, T.
Sternas, L.
Zaki, M.
Jacques, C.
Shah, J.
HAEMATOLOGICA, 2015, 100 : 507 - 508
[9] Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
Chen, Christine I.
Sutherland, Heather J.
Kotb, Rami
Sebag, Michael
White, Darrell J.
Bensinger, William
Gasparetto, Cristina J.
Leblanc, Richard
Venner, Christopher P.
Lentzsch, Suzanne
Schiller, Gary J.
Lipe, Brea
Del Col, Aldo
Shah, Jatin J.
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Kauffman, Michael G.
Shacham, Sharon
Bahlis, Nizar
BLOOD, 2018, 132
[10] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Richardson, Paul
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32

← 1 2 3 4 5 →